Accelerate Stock Analysis

AXDX
 Stock
  

USD 1.68  0.07  4.35%   

The current price rise of Accelerate Diagnosti could raise concerns from investors as the firm is trading at a share price of 1.68 on 101,500 in volume. The company management teams may have good odds in positioning the firm resources to exploit market volatility in October. The stock standard deviation of daily returns for 90 days investing horizon is currently 10.63. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Accelerate Diagnosti partners.
Please continue to Trending Equities.
  
The Accelerate Diagnosti stock analysis report makes it easy to digest most publicly released information about Accelerate Diagnosti and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Accelerate Stock analysis module also helps to analyze the Accelerate Diagnosti price relationship with some important fundamental indicators such as market cap and management efficiency.

Accelerate Stock Analysis Notes

About 33.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.4. Accelerate Diagnosti had not issued any dividends in recent years. The entity had 1:4 split on the 19th of November 1996. Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona. Accelerate Diagnosti operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 220 people. For more info on Accelerate Diagnosti please contact Lawrence Mehren at 520 365-3100 or go to www.acceleratediagnostics.com.

Accelerate Diagnosti Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Accelerate Diagnosti's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Accelerate Diagnosti or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Accelerate Diagnosti is way too risky over 90 days horizon
Accelerate Diagnosti may become a speculative penny stock
Accelerate Diagnosti appears to be risky and price may revert if volatility continues
Accelerate Diagnosti has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 12.22 M. Net Loss for the year was (67.65 M) with loss before overhead, payroll, taxes, and interest of (381 K).
Accelerate Diagnosti currently holds about 50.38 M in cash with (46.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.63.
Roughly 33.0% of the company shares are held by company insiders
Latest headline from news.northwestern.edu: New 35 million fund will accelerate the impact on society of Northwesterns nearly 1 billion in annual research - Northwestern Now

Accelerate Diagnosti Upcoming and Recent Events

Earnings reports are used by Accelerate Diagnosti to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Accelerate Diagnosti previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report22nd of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End22nd of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Accelerate Diagnosti SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Accelerate Diagnosti prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Accelerate Diagnosti investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Accelerate Diagnosti specific information freely available to individual and institutional investors to make a timely investment decision.
23rd of August 2022
Financial Statements and Exhibits. Other Events
View
15th of August 2022
Financial Statements and Exhibits. Unregistered Sales of Equity Securities. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Results of Operations and Financial Condition. Entry into a Material Definitive Agreement
View
30th of June 2022
Other Events
View
17th of May 2022
Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Completion of Acquisition or Disposition of Assets
View
16th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
25th of March 2022
Financial Statements and Exhibits. Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
View
21st of March 2022
Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
View
8th of March 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View

Accelerate Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Accelerate Diagnosti is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Accelerate Diagnosti backward and forwards among themselves. Accelerate Diagnosti's institutional investor refers to the entity that pools money to purchase Accelerate Diagnosti's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Citadel Advisors LlcDebt38.7 M25.2 M
Griffin Asset Management IncCommon SharesMM
Oracle Investment Management IncCommon Shares2.4 M2.4 M
Vanguard Group IncCommon Shares2.3 M2.3 M
Birchview Capital LpCommon Shares2.3 M2.2 M
Citadel Advisors LlcCommon Shares1.2 M1.2 M
Cannell CoCommon Shares1.1 M1.1 M
Citadel Advisors LlcPut Options686.9 K682 K
Cladis Investment Advisory LlcCommon Shares583.5 K579 K
Note, although Accelerate Diagnosti's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Accelerate Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 114.95 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Accelerate Diagnosti's market, we take the total number of its shares issued and multiply it by Accelerate Diagnosti's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (51.7) % which means that it has lost $51.7 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (837.84) %, meaning that it created substantial loss on money invested by shareholders. Accelerate Diagnosti management efficiency ratios could be used to measure how well accelerate diagnosti manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 28th of September, Accelerate Diagnosti shows the mean deviation of 7.57, and Risk Adjusted Performance of 0.1336. Accelerate Diagnosti technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down nineteen technical drivers for Accelerate Diagnosti, which can be compared to its rivals. Please confirm Accelerate Diagnosti standard deviation, as well as the relationship between the value at risk and kurtosis to decide if Accelerate Diagnosti is priced correctly, providing market reflects its regular price of 1.68 per share. Please also double-check Accelerate Diagnosti total risk alpha, which is currently at 1.94 to validate the company can sustain itself at a future point.

Accelerate Diagnosti Price Movement Analysis

The output start index for this execution was one with a total number of output elements of sixty. The Parabolic SAR indicator is used to determine the direction of Accelerate Diagnosti's momentum and the point in time when Accelerate Diagnosti has higher than normal probability directional change.
.

Accelerate Diagnosti Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Accelerate Diagnosti insiders, such as employees or executives, is commonly permitted as long as it does not rely on Accelerate Diagnosti's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Accelerate Diagnosti insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mertz Larry Michael over a month ago via Macroaxis 
Purchase by Mertz Larry Michael of 51749 shares of Accelerate Diagnosti
Burris Wayne over three months ago via Macroaxis 
Acquisition by Burris Wayne of 41958 shares of Accelerate Diagnosti subject to Rule 16b-3
Phillips Jack over three months ago via Macroaxis 
Exercise or conversion by Phillips Jack of 168396 shares of Accelerate Diagnosti subject to Rule 16b-3
Ron Price over three months ago via Macroaxis 
Exercise or conversion by Ron Price of 40755 shares of Accelerate Diagnosti subject to Rule 16b-3
Ron Price over three months ago via Macroaxis 
Exercise or conversion by Ron Price of 40755 shares of Accelerate Diagnosti subject to Rule 16b-3
Phillips Jack over three months ago via Macroaxis 
Acquisition by Phillips Jack of 888060 shares of Accelerate Diagnosti subject to Rule 16b-3
Phillips Jack over six months ago via Macroaxis 
Acquisition by Phillips Jack of 168396 shares of Accelerate Diagnosti subject to Rule 16b-3
Phillips Jack over six months ago via Macroaxis 
Exercise or conversion by Phillips Jack of 10000 shares of Accelerate Diagnosti subject to Rule 16b-3
Massarany Hany over six months ago via Macroaxis 
Purchase by Massarany Hany of 20000 shares of Accelerate Diagnosti
Jack Schuler over six months ago via Macroaxis 
Accelerate Diagnosti exotic insider transaction detected
Jack Schuler over six months ago via Macroaxis 
Accelerate Diagnosti exotic insider transaction detected
Jack Schuler over six months ago via Macroaxis 
Accelerate Diagnosti exotic insider transaction detected

Accelerate Diagnosti Predictive Daily Indicators

Accelerate Diagnosti intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Accelerate Diagnosti stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Accelerate Diagnosti Forecast Models

Accelerate Diagnosti time-series forecasting models is one of many Accelerate Diagnosti's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Accelerate Diagnosti's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Accelerate Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Accelerate Diagnosti prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Accelerate shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Accelerate Diagnosti. By using and applying Accelerate Stock analysis, traders can create a robust methodology for identifying Accelerate entry and exit points for their positions.
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona. Accelerate Diagnosti operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 220 people.

Current Accelerate Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Accelerate analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Accelerate analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
7.0Hold1Odds
Accelerate Diagnosti current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Accelerate analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Accelerate stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Accelerate Diagnosti, talking to its executives and customers, or listening to Accelerate conference calls.
Accelerate Analyst Advice Details

Accelerate Stock Analysis Indicators

Accelerate Diagnosti stock analysis indicators help investors evaluate how Accelerate Diagnosti stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Accelerate Diagnosti shares will generate the highest return on investment. By understating and applying Accelerate Diagnosti stock analysis, traders can identify Accelerate Diagnosti position entry and exit signals to maximize returns.
Quick Ratio6.39
Fifty Two Week Low0.5000
Revenue Growth17.50%
Shares Short Prior Month6.73M
Average Daily Volume Last 10 Day673.76k
Average Daily Volume In Three Month1.15M
Shares Percent Shares Out6.48%
Gross Margins-3.89%
Short Percent Of Float10.03%
Forward Price Earnings-3.93
Float Shares51.03M
Fifty Two Week High7.1900
Enterprise Value To Ebitda-2.69
Fifty Day Average1.7264
Two Hundred Day Average2.1084
Enterprise Value To Revenue14.32
Please continue to Trending Equities. Note that the Accelerate Diagnosti information on this page should be used as a complementary analysis to other Accelerate Diagnosti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for Accelerate Stock analysis

When running Accelerate Diagnosti price analysis, check to measure Accelerate Diagnosti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnosti is operating at the current time. Most of Accelerate Diagnosti's value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnosti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Accelerate Diagnosti's price. Additionally, you may evaluate how the addition of Accelerate Diagnosti to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Is Accelerate Diagnosti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Accelerate Diagnosti. If investors know Accelerate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Accelerate Diagnosti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Accelerate Diagnosti is measured differently than its book value, which is the value of Accelerate that is recorded on the company's balance sheet. Investors also form their own opinion of Accelerate Diagnosti's value that differs from its market value or its book value, called intrinsic value, which is Accelerate Diagnosti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Accelerate Diagnosti's market value can be influenced by many factors that don't directly affect Accelerate Diagnosti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Accelerate Diagnosti's value and its price as these two are different measures arrived at by different means. Investors typically determine Accelerate Diagnosti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Accelerate Diagnosti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.